standard quadruple therapy — Competitive Intelligence Brief

standard quadruple therapy (standard quadruple therapy) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial combination therapy. Area: Infectious Disease.

marketed Antimicrobial combination therapy Infectious Disease Small molecule

Target snapshot

standard quadruple therapy (standard quadruple therapy) — Les Laboratoires des Médicaments Stériles. Standard quadruple therapy combines four antimicrobial agents to treat infections, typically used in tuberculosis or Helicobacter pylori eradication.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
standard quadruple therapy TARGET	standard quadruple therapy	Les Laboratoires des Médicaments Stériles	marketed	Antimicrobial combination therapy
Bismuth-based susceptibility-guided treatment	Bismuth-based susceptibility-guided treatment	National Cheng-Kung University Hospital	marketed	Antimicrobial combination therapy (bismuth-based)	Helicobacter pylori cell wall and bacterial proteins
Modified bismuth-containing eradication treatment	Modified bismuth-containing eradication treatment	Athens Medical Center	marketed	Antimicrobial combination therapy	Helicobacter pylori cell wall and urease enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial combination therapy class)

1. Athens Medical Center · 1 drug in this class
2. Les Laboratoires des Médicaments Stériles · 1 drug in this class